ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: antinuclear antibody

New Study Examines Treatment Options for Incomplete Lupus Erythematous

Catherine Kolonko  |  

A recent study explored medical concerns for patients who have lupus markers, but fall short of meeting enough criteria for official disease classification. Investigators at the Oklahoma Medical Research Foundation conducted a large study to explore current treatments of patients with incomplete lupus erythematous (ILE) and to compare antibody characteristics to healthy people and patients…

Updates on Managing Lupus Complications

  |  

SAN DIEGO—To manage patients with systemic lupus erythematous (SLE), rheuma­tologists must be aware of potentially serious complications affecting many organ systems. On Nov. 7 at the 2017 ACR/ARHP Annual Meeting, two experts offered insights on cardiovascular and hematological complications of lupus. Myocardial Disease in Lupus Lupus patients are at increased risk for heart-related complications, especially…

Lupus B Cell Research Points Toward Targeted Therapies

  |  

SAN DIEGO—B cell signaling goes awry in many patients with systemic lupus erythematosus (SLE), triggering pathogenic autoimmune responses and clinical disease. At the Rheumatology Research Foundation’s 2017 Evelyn V. Hess Memorial Lecture, held on Nov. 5 at the ACR/ARHP Annual Meeting, researcher Ignacio Sanz, MD, discussed B cells’ role in this complex disease. Because lupus…

Key Findings in Basic Science This Year Hold Promise for Potential Rheumatology Therapies

  |  

SAN DIEGO—After sifting through the nitty-gritty of the rheumatic disease literature on basic science, Richard Pope, MD—professor of medicine specializing in rheumatology at Northwestern University Feinberg School of Medicine—underscored several findings he thought stood out from the pack in his Year in Review talk at the 2017 ACR/ARHP Annual Meeting. He reviewed findings from November…

2017 in Review: Key Findings in Basic Science Highlighted at the ACR/ARHP Annual Meeting

  |  

During the ACR/ARHP Annual Meeting, Richard Pope, MD, highlighted some of the top scientific literature on rheumatic disease from 2017. The review session discussed research on the effects of microglia on the central nervous system of SLE patients, the role of adenosine in osteoarthritis and more…

BYUNG H. BAN, DO

Rheumatology Case Report: Immune-Related Aortitis Associated with Ipilimumab

Byung H. Ban, DO, Jayne L. Crowe, MD, & Robert M. Graham, MD  |  

Ipilimumab (Yervoy) is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen 4 (CTLA-4). It was the first drug to demonstrate a survival benefit in advanced melanoma and was approved by the FDA in 2011.1 By blocking the CTLA-4 receptor, ipilimumab enhances the immune response against tumors via cytotoxic T lymphocyte activation and proliferation.2 However, immunopotentiating…

How to Diagnose Antisynthetase Syndrome

How to Diagnose Antisynthetase Syndrome

Quretul Quresh, MD, & Stephen Lindsey, MD  |  

Antisynthetase syndrome (AS) is strongly associated with the presence of antibodies to aminoacyl-transfer RNA (tRNA) synthetases (ARSs) that are implicated in the pathogenesis of myositis and interstitial lung disease (ILD). Antibodies against eight antisynthetases have been identified and are detected in 16–26% of patients with idiopathic inflammatory myopathies (IIM).1 Serum assays for five of these…

ACR, EULAR Approve New Classification Criteria for Primary Sjögren’s Syndrome

  |  

Classification criteria for primary Sjögren’s syndrome (SS) have been approved by the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR), validating an international set of classification criteria for SS using standards set by both organizations. Those criteria can now be found in the 2016 ACR/EULAR Classification Criteria for Primary Sjögren’s Syndrome: A…